Zobrazeno 1 - 10
of 1 956
pro vyhledávání: '"Renal Anemia"'
Publikováno v:
The Journal of Clinical Hypertension, Vol 26, Iss 12, Pp 1375-1383 (2024)
ABSTRACT Hypoxia‐inducible factor prolyl hydroxylase (HIF‐PH) inhibitors are a new class of agents for the treatment of anemia in chronic kidney disease (CKD). Unlike traditional treatments such as erythropoiesis‐stimulating agents (ESAs), HIF
Externí odkaz:
https://doaj.org/article/5f8519f8c9ab46f6af2df935715b317d
Publikováno v:
Renal Failure, Vol 46, Iss 1 (2024)
Objective To explore independent influencing factors for clinical efficacy of roxadustat in hemodialysis patients.Methods Hemodialysis patients treated with roxadustat were enrolled. The plasma trough concentrations of roxadustat were measured using
Externí odkaz:
https://doaj.org/article/806249233330466e840274b928e5d83b
Autor:
Jie Liu, Shuang Li, Fan Yang, Tianyu Li, Rui Li, Yousuf Waheed, Chen Meng, Shulin Li, Kun Liu, Yanshan Tong, Haisheng Xu, Chuankuo Tian, Xinglei Zhou
Publikováno v:
The Korean Journal of Internal Medicine, Vol 39, Iss 3, Pp 488-500 (2024)
Background/Aims Roxadustat, an oral medication for treating renal anemia, is a hypoxia-inducible factor prolyl hydroxylase inhibitor used for regulating iron metabolism and promoting erythropoiesis. To investigate the efficacy and safety of roxadusta
Externí odkaz:
https://doaj.org/article/f3c4c542145e48ca882452efcb86fd45
Publikováno v:
Expert Opinion on Pharmacotherapy; Jul2024, Vol. 25 Issue 10, p1291-1299, 9p
Autor:
Guoguang Gu, Yanping Li, Yunyun Hu, Hengyi Zhao, Xingdong Wang, Xiaomin Li, Xinran Zhang, Hong Zhu, Xiaohua Dai, Xingxing Liu, Liyan Miao, Jianguo Zhu, Yongfu Hang
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
AimsTo investigate the prevalence and influencing factors of drug-related problems (DRPs) in inpatients with kidney disease to provide reference data for pharmaceutical care.MethodsThe basic information, diagnoses, and medication reconciliation (MR)
Externí odkaz:
https://doaj.org/article/9c0cee5e535d40bb879faea6517d5a80
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract The determinants of roxadustat treatment failure in renal anemia remain elusive. This study sought to develop a nomogram for predicting the risk of treatment failure of roxadustat in peritoneal dialysis (PD) with renal anemia. A retrospectiv
Externí odkaz:
https://doaj.org/article/9399abba32f14e8d86e6659482ce286a
Autor:
Nobuaki Ariyoshi, Fumiaki Higashijima, Makiko Wakuta, Tadahiko Ogata, Manami Ohta, Kazuhiro Kimura
Publikováno v:
Case Reports in Ophthalmology, Vol 15, Iss 1, Pp 256-264 (2024)
Introduction: Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors, used in the treatment of renal anemia, hold the potential to increase the production of vascular endothelial growth factors. Therefore, HIF-PH inhibitors may exacerbate re
Externí odkaz:
https://doaj.org/article/a822da87b0d04083a001a2bef00fe2df